Lv4
408 积分 2021-09-17 加入
Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature
28天前
已完结
Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
28天前
已关闭
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
29天前
已完结
Immune checkpoint inhibitor‐associated inflammatory arthritis
29天前
已关闭
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
29天前
已完结
Modulation of T Cell Regulation by Interleukin-2 Agonists: Mechanisms and Clinical Implications
29天前
已完结
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
1个月前
已完结
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia
1个月前
已完结
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia
1个月前
已完结
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
